Abstract：Objective To explore the effect of glucocorticoid therapy on the growth and development of children with bronchiolitis. Methods A total of 143 children with bronchiolitis who were treated with glucocorticoids from February 2017 to March 2018 were enrolled. The medical data were retrospectively collected, including height, weight, course of the disease, and diagnosis and treatment plan at initial admission. After three years of treatment, physical development indices were measured, growth and development were evaluated by Z-score, and related hematological parameters were measured, including osteocalcin, serum phosphorus, and insulin-like growth factor-1. Results As for the children with bronchiolitis, the incidence rates of growth retardation and obesity increased significantly after three years of glucocorticoid therapy (P<0.05). The children treated with glucocorticoids for ≥29 days showed a significantly higher incidence rate of obesity than those treated with glucocorticoids for <29 days (P<0.05), while nebulized glucocorticoid treatment had no effect on the growth and development (P>0.05). Compared with the children with growth retardation, the children with normal development had significantly higher levels of serum phosphorus and insulin-like growth factor-1 (P<0.05). Conclusions Glucocorticoid therapy can adversely affect long-term growth and development in children with bronchiolitis.
AILI Zha-Yidan,ABUDUHAER Abulaiti. Effect of glucocorticoid therapy on long-term growth and development of children with bronchiolitis[J]. CJCP, 2022, 24(3): 261-265.
Li X, Willem L, Antillon M, et al. Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries[J]. BMC Med, 2020, 18(1): 82. PMID: 32248817. PMCID: PMC7132892. DOI: 10.1186/s12916-020-01537-6.
American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis[J]. Pediatrics, 2006, 118(4): 1774-1793. PMID: 17015575. DOI: 10.1542/peds.2006-2223.
Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis[J]. Pediatrics, 2014, 134(5): e1474-e1502. PMID: 25349312. DOI: 10.1542/peds.2014-2742.
Song Y, Wang HJ, Ma J, et al. BMI-for-age Z-score distribution shifts among Chinese children: gender disparity[J]. Obesity (Silver Spring), 2014, 22(4): 1187-1193. PMID: 24318807. DOI: 10.1002/oby.20676.
Sepp? S, Tenhola S, Voutilainen R. Association of serum total osteocalcin concentrations with endogenous glucocorticoids and insulin sensitivity markers in 12-year-old children: a cross-sectional study[J]. Front Endocrinol (Lausanne), 2019, 10: 798. PMID: 31803143. PMCID: PMC6877498. DOI: 10.3389/fendo.2019.00798.
Kannisto S, Korppi M, Arikoski P, et al. Biochemical markers of bone metabolism in relation to adrenocortical and growth suppression during the initiation phase of inhaled steroid therapy[J]. Pediatr Res, 2002, 52(2): 258-262. PMID: 12149504. DOI: 10.1203/00006450-200208000-00019.
Ramshanker N, Aagaard M, Hjortebjerg R, et al. Effects of prednisolone on serum and tissue fluid IGF-I receptor activation and post-receptor signaling in humans[J]. J Clin Endocrinol Metab, 2017, 102(11): 4031-4040. PMID: 28945869. DOI: 10.1210/jc.2017-00696.
